Engineering Psychoplastogens: Toward a Safer Alternative for Treating Depression
Identification of psychoplastogenic isoDMT analogs is a concrete step forward in using psychedelics for treating patients who suffer from depression.
Health
Researchers Synthesize Novel Compound, Tabernanthalog, a Non-Hallucinogenic Ibogaine Analog
This compound exhibits reduced cardiotoxicity, psychoplastogen characteristics, and potential therapeutic effects in animal models.
What is the Mystical Experience Questionnaire?
The MEQ is a self-report measure that provides insight into a key aspect of the psychedelic experience.
The Effects of Psilocybin on Morality and Empathy
This study is the first of its kind to suggest that psilocybin enhances emotional empathy but does not affect moral behavior.
Are the Subjective Effects of Psychedelics Necessary for Their Therapeutic Benefits?
Researchers at the forefront of psychedelic science put forth their arguments in this important debate.
Compassionate Use – Psychedelic Therapy for Those Who Can’t Wait
“Obviously, bureaucracy is not a human being. People have compassion. Bureaucracies don’t always have compassion.' -- Spencer Hawkswell
Equity and Accessibility of MDMA-Assisted Therapy
Psychedelic medicine continues to move forward, but minority communities are being left behind.
Exploratory Study Indicates Psilocybin Provides Relief for Migraines
Interestingly, changes in migraine frequency were not correlated with the intensity of the acute psychotropic effects.
Methoxetamine: Cousin of Ketamine
The characterization of methoxetamine, a ketamine analog, and how its action on the serotonin system sets it apart.
DMT Research Affords New Hope for Stroke Victims
A recent study shows DMT reduces the cellular stress caused by a stroke and speeds up recovery time in rats. These findings highlight the expanding therapeutic potential of DMT regarding neurological disorders.